Electroporation News and Research

RSS

Breakthrough in CRISPR delivery promises safer gene editing

Recent research in PNAS highlights advancements in non-viral, cell-specific delivery methods for CRISPR-Cas systems, emphasizing their potential to enhance research and gene therapy applications by minimizing risks associated with off-target effects and improving targeted delivery.

7 Mar 2024

Scientists coax a deadly bacterium to destroy itself from the inside out

Northwestern University researchers have successfully coaxed a deadly pathogen to destroy itself from the inside out.

31 Jan 2024

Overcoming adherence challenges: Innovative patch enables controlled drug delivery

A breakthrough in transdermal drug delivery.

17 Jan 2024

New study provides convincing evidence of the essential role of cylicins in sperm development and fertility

Researchers investigated the Role of Cylicins in Spermiogenesis and Male Fertility in Mice and Humans through Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9) Gene Editing.

30 Nov 2023

MaxCyte joins the alliance for mRNA medicines (AMM) as a founding member

MaxCyte, Inc. today announced that it has joined the Alliance for mRNA Medicines, as a founding member.

From MaxCyte, Inc. 22 Nov 2023

MaxCyte joins the Alliance for mRNA Medicines (AMM) as a founding member

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced that it has joined the Alliance for mRNA Medicines (AMM), as a founding member.

From MaxCyte, Inc. 16 Nov 2023

Recent Advancements in Cell Based Therapy

In this interview, NewsMedical talks to James Brady about cell-based therapy and how the field of genetic engineering transformed.

From MaxCyte, Inc. 11 Oct 2023

Arrayed CRISPR Screening for Revolutionizing Target Discovery

In this interview conducted at SLAS EU 2023 in Brussels, Belgium, we spoke to Ulrike Kuenzel, Associate Director in the Functional Genomics department at AstraZeneca about the application of arrayed CRISPR screening for target identification and more.

From Society for Laboratory Automation and Screening (SLAS) 27 Sep 2023

Pulsed field ablation safe, effective for the treatment of paroxysmal atrial fibrillation

Pulsed field ablation (PFA) is as effective and safe as conventional thermal ablation for the treatment of paroxysmal atrial fibrillation (AF), according to late breaking research presented in a Hot Line session today at ESC Congress 2023.

28 Aug 2023

Virginia Tech researchers receive $2.6M NIH grant to study new pancreatic cancer treatment

Only about 10 percent of patients survive as long as five years after a diagnosis of pancreatic cancer.

14 Aug 2023

MaxCyte signs strategic platform license with Lyell Immunopharma

From MaxCyte, Inc. 10 Aug 2023

MaxCyte and Vittoria Biotherapeutics sign strategic platform license to advance next generation cellular therapies

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, and Vittoria Biotherapeutics (Vittoria), a leading edge, gene-edited cell therapeutics company with novel platform technologies poised to develop a pipeline of highly differentiated cellular therapies for both oncology and immunology indications, today announced the signing of a strategic platform license (SPL) of MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to Vittoria Biotherapeutics.

From MaxCyte, Inc. 10 Aug 2023

MaxCyte signs strategic platform license with prime medicine to advance next-generation gene editing therapies for patients

From MaxCyte, Inc. 10 Aug 2023

Is green leaf biomass a viable and sustainable source of protein?

In a recent study published in the journal Nutrients, researchers at North Carolina State University reviewed studies on underutilized sources of plant proteins and discussed strategies to enhance yields, extract nutrients and influence the demand and acceptance of new protein sources, especially green leaf biomass.

14 Mar 2023

mRNA vaccine methodologies: Production, value and spectrometer use

To be decided by the editor

From Thermo Fisher Scientific – Materials & Structural Analysis 16 Dec 2022

Exploring synthetic engineering of bacteriophages

In a new study, researchers demonstrated biological bacteriophage containment and synthetic engineering.

24 Nov 2022

Novel linear DNA SARS-CoV-2 vaccine using electroporation-aided vaccine delivery reveals lower viral shedding in ferrets

Researchers evaluated the efficacy, immunogenicity, and safety of a novel SARS-CoV-2 linear deoxyribonucleic acid vaccine in ferret models delivered using intramuscular injection and electroporation.

3 Oct 2022

Needle-free jet injection of novel COVID-19 DNA vaccine shows promise in animal model

In a recent study posted to the bioRxiv* server, researchers at the United States Army Medical Research Institute of Infectious Diseases evaluated the immunogenicity of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) deoxyribonucleic acid (DNA) vaccine, nCOV-S(JET), in rhesus macaques

18 Sep 2022

MaxCyte signs strategic platform license with LG Chem to advance its allogeneic CAR-T programs

MaxCyte, Inc., a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announces the signing of a strategic platform license (SPL) with LG Chem Ltd., a globally diversified chemical company established in petrochemical, advanced materials and bio-technology, aiming to create new value for its customers based on science.

From MaxCyte, Inc. 13 Jul 2022

The potential of DNA-based SARS-CoV-2 vaccine candidates

Researchers evaluated the immunogenicity of DNA-based candidate vaccines against SARS-CoV-2 in mice.

28 Jun 2022

Electroporation News and Research

Breakthrough in CRISPR delivery promises safer gene editing

Scientists coax a deadly bacterium to destroy itself from the inside out

Overcoming adherence challenges: Innovative patch enables controlled drug delivery

New study provides convincing evidence of the essential role of cylicins in sperm development and fertility

MaxCyte joins the alliance for mRNA medicines (AMM) as a founding member

MaxCyte joins the Alliance for mRNA Medicines (AMM) as a founding member

Recent Advancements in Cell Based Therapy

Arrayed CRISPR Screening for Revolutionizing Target Discovery

Pulsed field ablation safe, effective for the treatment of paroxysmal atrial fibrillation

Virginia Tech researchers receive $2.6M NIH grant to study new pancreatic cancer treatment

MaxCyte signs strategic platform license with Lyell Immunopharma

MaxCyte and Vittoria Biotherapeutics sign strategic platform license to advance next generation cellular therapies

MaxCyte signs strategic platform license with prime medicine to advance next-generation gene editing therapies for patients

Is green leaf biomass a viable and sustainable source of protein?

mRNA vaccine methodologies: Production, value and spectrometer use

Exploring synthetic engineering of bacteriophages

Novel linear DNA SARS-CoV-2 vaccine using electroporation-aided vaccine delivery reveals lower viral shedding in ferrets

Needle-free jet injection of novel COVID-19 DNA vaccine shows promise in animal model

MaxCyte signs strategic platform license with LG Chem to advance its allogeneic CAR-T programs

The potential of DNA-based SARS-CoV-2 vaccine candidates

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News